ClinicalTrials.gg
TerminatedNCT01101906Updated Nov 20, 2024

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

A Phase 2 interventional study of OSI-906 and Placebo in Advanced Hepatocellular Carcinoma (HCC), sponsored by Astellas Pharma Inc. Terminated at 41 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Company decided not to pursue the development of this drug in this patient population at this time

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Carcinoma, Hepatocellular with a site in France — 54 open to participants now, 85 under way, 14 of them phase 3. Carcinoma, Hepatocellular · France.

Enrollment
184th of 215
23 · median 136
Started
2011
with 9 others
Phase 2
50 of 284
7 open now
Registered
40th of 284
by date

Among the 284 studies in Carcinoma, Hepatocellular with a site in France, this one is the 184th largest by enrollment of the 215 interventional ones that give a count, is one of 10 that started in 2011, is one of 50 in phase 2, and was the 40th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

54 of the 284 studies in Carcinoma, Hepatocellular with a site in France are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Carcinoma, Hepatocellular with a site in France, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.

Read the detailed description

Adult patients with advanced HCC previously treated with sorafenib will be randomized 2:1 to receive either single agent OSI-906 or placebo

03

Conditions studied

  • Advanced Hepatocellular Carcinoma (HCC)

Keywords

  • HCC
  • OSI-906
  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of advanced HCC. Clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients is acceptable. For patients without cirrhosis histological confirmation is mandatory
  • Patients must have received prior systemic treatment for advanced HCC with sorafenib and had confirmed disease progression or had discontinued sorafenib due to a drug related toxicity
  • Patient has received their last dose of sorafenib at least 14 days prior to randomization
  • Patient has recovered from sorafenib or agent related toxicity to ≤ grade 2
  • according to (version 1.1)
  • (ECOG) Performance Status (PS) 0 - 1
  • Status A or B(7)
  • Barcelona Clinic Liver Cancer (BCLC) stage B/C
  • Previous local therapy (eg, surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) is permitted if ≥ 21 days before randomization
  • Fasting glucose ≤ 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if the dose has been stable for ≥ 4 weeks at the time of randomization
  • Following laboratory parameters (determined by laboratory):

    • ≥ 60 x 10\^9/L
    • ≥ 8.5 g/dL
    • Absolute neutraphil count (ANC) ≥ 1.5 x 10\^9/L
    • Potassium within normal limits (supplementation may be used)
    • Partial thrombopastin time () ≤ 2.3 x (ULN)
    • Magnesium within normal limits (supplementation may be used)
    • Calcium within normal limits (supplementation may be used)
  • Adequate organ function (for a HCC population):

    • Liver function test (LFT) ≤ 5 x ULN
    • Albumin ≥ 2.8 g/dL
    • Total ≤ 2.8 mg/dL
    • Creatinine ≤ 1.5 x ULN
    • International normalized ratio (INR) ≤ 2.3
  • Estimated ≥ 12 weeks based on an investigator assessment of recent changes in laboratory values, performance status, and other clinical criteria
  • Patients, both males and females, with (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective measures throughout the study. Women of must provide a negative pregnancy test (serum or urine) within 14 days prior to randomization
  • Patients must provide written to participate in the study
  • Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization. A minimum of 21 days must have elapsed between the end of radiotherapy and randomization; and
  • Prior surgery is permitted provided that the surgery was done ≤ 28 days prior to randomization and adequate wound healing has occurred prior to randomization

Exclusion criteria

Exclusion Criteria:

  • B (8 - 9) or C
  • Patients who are candidates for potentially curative intervention (ie, surgical resection or transplantation)
  • Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy
  • Prior insulin-like growth factor - 1 receptor (IGF-1R) therapy
  • Patients requiring interferon
  • Patients with uncontrolled symptomatic ascites
  • Prior agent within 21 days prior to randomization
  • History of poorly controlled gastrointestinal disorders that could affect the absorption of study drug (eg, Crohn's disease, ulcerative colitis, etc)
  • History of organ allograft including liver transplant
  • other than HCC within the past 3 years:

    • Exceptions: resected basal cell or squamous cell carcinoma of the skin, cured in situ cervical carcinoma, cured ductal carcinoma in situ of the breast, and/or cured superficial bladder cancer
  • History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded
  • interval at screening ≥ 450 msec
  • Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades List' on www.azcert.org/medical-pros/drug-lists/by category.cfm)are prohibited within 14 days prior to randomization
  • Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded
  • History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability
  • Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization) that would impair the ability of the patient to receive study drug
  • History of (HIV) infection or acquired immune deficiency syndrome (AIDS)-related illness or serious acute or chronic illness
  • History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide
  • Pregnant or breast-feeding females
  • Symptomatic that are not stable, require , are potentially life threatening, or that have required radiation within 28 days prior to randomization; and/or
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Arm A: OSI-906

    150 mg BID

    Drug: OSI-906

  • Placebo comparator
    Arm B: Placebo

    Placebo BID

    Drug: Placebo

Interventions

  • OSI-906 administered orally

  • DrugPlacebo

    Matching placebo administered orally

06

What researchers measure

Primary outcomes

  1. Time to progression (TTP)

    Time from randomization to radiological disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 20 months

Secondary outcomes

  1. Overall Survival (OS)

    Date of randomization until the documented date of death

    Time frame: 23 months

  2. Progression Free Survival (PFS)

    Time from randomization to radiological disease progression based on RECIST version 1.1 assessed by investigator or death due to any cause whichever occurs first

    Time frame: 23 months

  3. Time to Progression (including clinical progression) (TTPc)

    Time from randomization to progression (either radiological disease progression based on RECIST version 1.1 or symptomatic clinical progression as assessed by investigator)

    Time frame: 23 months

  4. Disease Control Rate (DCR)

    Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease based on RECIST version 1.1 criteria

    Time frame: 23 months

  5. Overall Response Rate

    Proportion of patients with a best overall response of CR or PR based on RECIST version 1.1 criteria

    Time frame: 23 months

  6. Time to progression in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HVC)

    Time frame: 23 months

  7. Progression Free Survival in patients with HBV and/or HCV

    Time frame: 23 months

  8. Overall Survival in patients with HBV and/or HCV

    Time frame: 23 months

  9. Overall Response Rate in patients with HBV and/or HCV

    Time frame: 23 months

  10. Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events

    Time frame: 23 months

07

Study locations

41 sites
  • University of California - Los Angeles
    Los Angeles, California 90095, United States
  • Tulane University Health Services Center
    New Orleans, Louisiana 70112, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Seattle Cancer Care Alliance University of Washington
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 52336, United States
  • Cliniques Universitaires Saint-Luc
    Brussells, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Hopital Jean Verdier - Dervice d'Hepato-Gastroenterologie
    Bondy Cedex, 93143, France
  • Hôpital Henri Mondor
    Creteil cedex, 94010, France
  • Hopital de la Timone
    Marseille Cedex 5, 13385, France
  • Hopital l'Archet 2
    Nice cedex 03, 6202, France
  • Hôpital Saint-Antoine
    Paris cedex 12, 75012, France
  • Hôpital de Tenon
    Paris cedex 12, 75020, France
  • Centre Rene Gauducheau
    Saint Herblain cedex, 44805, France
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • Universitätsklinikum Halle
    Halle, 06097, Germany
  • Universitatsklinikum des Saarlandes
    Homburg, 66421, Germany
  • Universitätsklinikum Magdeburg A.ö.R.
    Magdeburg, 39120, Germany
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Fondazione Ca' Granda Ospedale Maggiore Policlinico, Divisione di Gastroenterologia I
    Milano, 20122, Italy
  • Ospedale Fatebenefratelli, Dipartimento Medicina Interna
    Napoli, 80123, Italy
  • IRCCS Istituto Nazionale per lo studio e la cura dei tumori Fondazione G. Pascale-SSD Epatobiliare
    Napoli, 80131, Italy
  • Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione ISMETT-Dipartimento di Epatologia e Gastroenterologia
    Palermo, 90127, Italy
  • Pusan National University Hospital
    Busan, 602-739, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 700-721, Korea, Republic of
  • National Cancer Center
    Goyang-si, 410-769, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-774, Korea, Republic of
  • Severance Hospital
    Seoul, 120-752, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Singapore General Hospital
    Singapore, 169608, Singapore
  • Johns Hopkins Singapore International Medical Centre
    Singapore, 308433, Singapore
  • Hospital Clinico Universitario de Santiago de Compostela
    Santiago de Compostela, Coruna 15706, Spain
  • Hospital Clinic Provincial
    Barcelona, 08036, Spain
  • Hospital Puerta de Hierro Majadahonda
    Madrid, 28220, Spain
  • Clinica Universitaria de Navarra
    Pamplona, 31008, Spain
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 807, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • China Medical University Hospital
    Taichung, Taiwan
  • Chang Gung Medical Foundation LinKou Branch
    TaoYuan, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Nov 2011, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2010
First posted
Apr 12, 2010
StartActual
Jan 10, 2011
Primary completionActual
Nov 4, 2011
CompletionActual
Dec 28, 2011
Results delay requested
Dec 10, 2012
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01101906
Responsible party
Sponsor
First posted
Apr 12, 2010
Start date
Jan 10, 2011
Primary completion
Nov 4, 2011
Completion
Dec 28, 2011
Last update
Nov 20, 2024

Study contacts

Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linsitinib

Start the discussion